The location of COVID vaccine, which was approved for phase 1 of clinical trial by South Korea's bio-venture Quratis on the 19th, is controversial. Quratis vaccine is the first of its kind in South Korea, similar to Pfizer and Moderna. However, the MFDS says the vaccine is an overseas development product and discriminates against other domestic development products.

On the 20th, the MFDS approved Phase 1 clinical trial plan for QTP104. The clinical trial will be conducted for 36 people at Gangnam Severance Hospital, which is aimed at increasing capacity, multiplying institutions, disclosing and phase 1 of clinical trials to evaluate the safety of vaccines to prevent COVID-19 among healthy adults.